A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Inclusion Criteria

• •≥ 18 years or legal adult.
• •Pathologically confirmed diagnosis of locally advanced or metastatic NSCLC with EGFR (classical, atypical, exon20 insertion) or HER2 mutations in the kinase domain of exons 18, 19, 20, or 21. EGFR mutations include activating and acquired EGFR resistance mutations that might form compound mutations.
• •Had received standard therapies.
• •Has at least 1 measurable target extracranial lesion according to RECIST v1.1.
• •Eastern Cooperative Oncology Group Performance Status ≤ 1.
• •Has a life expectancy of ≥ 3 months.